Kaempferol Inhibits Angiogenesis by Suppressing HIF-1α and VEGFR2 Activation via ERK/p38 MAPK and PI3K/Akt/mTOR Signaling Pathways in Endothelial Cells

Kaempferol has been shown to inhibit vascular formation in endothelial cells. However, the underlying mechanisms are not fully understood. In the present study, we evaluated whether kaempferol exerts antiangiogenic effects by targeting extracellular signal-regulated kinase (ERK)/p38 mitogen-activate...

Full description

Saved in:
Bibliographic Details
Published inPreventive nutrition and food science Vol. 22; no. 4; pp. 320 - 326
Main Author Kim, Gi Dae
Format Journal Article
LanguageEnglish
Published Korea (South) 한국식품영양과학회 01.12.2017
The Korean Society of Food Science and Nutrition
Subjects
Online AccessGet full text
ISSN2287-1098
2287-8602
DOI10.3746/pnf.2017.22.4.320

Cover

Abstract Kaempferol has been shown to inhibit vascular formation in endothelial cells. However, the underlying mechanisms are not fully understood. In the present study, we evaluated whether kaempferol exerts antiangiogenic effects by targeting extracellular signal-regulated kinase (ERK)/p38 mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathways in endothelial cells. Endothelial cells were treated with various concentrations of kaempferol for 24 h. Cell viability was determined by the 3- (4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay; vascular formation was analyzed by tube formation, wound healing, and mouse aortic ring assays. Activation of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor receptor 2 (VEGFR2), ERK/p38 MAPK, and PI3K/Akt/mTOR was analyzed by Western blotting. Kaempferol significantly inhibited cell migration and tube formation in endothelial cells, and suppressed microvessel sprouting in the mouse aortic ring assay. Moreover, kaempferol suppressed the activation of HIF-1α, VEGFR2, and other markers of ERK/p38 MAPK and PI3K/Akt/mTOR signaling pathways in endothelial cells. These results suggest that kaempferol inhibits angiogenesis by suppressing HIF-1α and VEGFR2 activation via ERK/p38 MAPK and PI3K/Akt/mTOR signaling in endothelial cells.
AbstractList Kaempferol has been shown to inhibit vascular formation in endothelial cells. However, the underlying mechanisms are not fully understood. In the present study, we evaluated whether kaempferol exerts antiangiogenic effects by targeting extracellular signal-regulated kinase (ERK)/p38 mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathways in endothelial cells. Endothelial cells were treated with various concentrations of kaempferol for 24 h. Cell viability was determined by the 3- (4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay; vascular formation was analyzed by tube formation, wound healing, and mouse aortic ring assays. Activation of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor receptor 2 (VEGFR2), ERK/p38 MAPK, and PI3K/Akt/mTOR was analyzed by Western blotting. Kaempferol significantly inhibited cell migration and tube formation in endothelial cells, and suppressed microvessel sprouting in the mouse aortic ring assay. Moreover, kaempferol suppressed the activation of HIF-1α, VEGFR2, and other markers of ERK/p38 MAPK and PI3K/Akt/mTOR signaling pathways in endothelial cells. These results suggest that kaempferol inhibits angiogenesis by suppressing HIF-1α and VEGFR2 activation via ERK/p38 MAPK and PI3K/Akt/mTOR signaling in endothelial cells. KCI Citation Count: 0
Kaempferol has been shown to inhibit vascular formation in endothelial cells. However, the underlying mechanisms are not fully understood. In the present study, we evaluated whether kaempferol exerts antiangiogenic effects by targeting extracellular signal-regulated kinase (ERK)/p38 mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathways in endothelial cells. Endothelial cells were treated with various concentrations of kaempferol for 24 h. Cell viability was determined by the 3- (4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay; vascular formation was analyzed by tube formation, wound healing, and mouse aortic ring assays. Activation of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor receptor 2 (VEGFR2), ERK/p38 MAPK, and PI3K/Akt/mTOR was analyzed by Western blotting. Kaempferol significantly inhibited cell migration and tube formation in endothelial cells, and suppressed microvessel sprouting in the mouse aortic ring assay. Moreover, kaempferol suppressed the activation of HIF-1α, VEGFR2, and other markers of ERK/p38 MAPK and PI3K/Akt/mTOR signaling pathways in endothelial cells. These results suggest that kaempferol inhibits angiogenesis by suppressing HIF-1α and VEGFR2 activation via ERK/p38 MAPK and PI3K/Akt/mTOR signaling in endothelial cells.
Kaempferol has been shown to inhibit vascular formation in endothelial cells. However, the underlying mechanisms are not fully understood. In the present study, we evaluated whether kaempferol exerts antiangiogenic effects by targeting extracellular signal-regulated kinase (ERK)/p38 mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathways in endothelial cells. Endothelial cells were treated with various concentrations of kaempferol for 24 h. Cell viability was determined by the 3- (4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay; vascular formation was analyzed by tube formation, wound healing, and mouse aortic ring assays. Activation of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor receptor 2 (VEGFR2), ERK/p38 MAPK, and PI3K/Akt/mTOR was analyzed by Western blotting. Kaempferol significantly inhibited cell migration and tube formation in endothelial cells, and suppressed microvessel sprouting in the mouse aortic ring assay. Moreover, kaempferol suppressed the activation of HIF-1α, VEGFR2, and other markers of ERK/p38 MAPK and PI3K/Akt/mTOR signaling pathways in endothelial cells. These results suggest that kaempferol inhibits angiogenesis by suppressing HIF-1α and VEGFR2 activation via ERK/p38 MAPK and PI3K/Akt/mTOR signaling in endothelial cells.Kaempferol has been shown to inhibit vascular formation in endothelial cells. However, the underlying mechanisms are not fully understood. In the present study, we evaluated whether kaempferol exerts antiangiogenic effects by targeting extracellular signal-regulated kinase (ERK)/p38 mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathways in endothelial cells. Endothelial cells were treated with various concentrations of kaempferol for 24 h. Cell viability was determined by the 3- (4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay; vascular formation was analyzed by tube formation, wound healing, and mouse aortic ring assays. Activation of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor receptor 2 (VEGFR2), ERK/p38 MAPK, and PI3K/Akt/mTOR was analyzed by Western blotting. Kaempferol significantly inhibited cell migration and tube formation in endothelial cells, and suppressed microvessel sprouting in the mouse aortic ring assay. Moreover, kaempferol suppressed the activation of HIF-1α, VEGFR2, and other markers of ERK/p38 MAPK and PI3K/Akt/mTOR signaling pathways in endothelial cells. These results suggest that kaempferol inhibits angiogenesis by suppressing HIF-1α and VEGFR2 activation via ERK/p38 MAPK and PI3K/Akt/mTOR signaling in endothelial cells.
Author Gi Dae Kim
Author_xml – sequence: 1
  givenname: Gi Dae
  surname: Kim
  fullname: Kim, Gi Dae
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29333385$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002303606$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kt9u0zAUxiM0xMbYA3CDfIM0LtL6TxI7N0hRabeqg1Zd4dZybSc1TZwQp0V9E15jL7Jnwv2zCbjAN8eSf9_36fic18GZra0OgrcI9giNkn5j8x6GiPYw7kU9guGL4AJjRkOWQHx2uiOYsvPgyrnvEEKEcBpj-io4xynxh8UXwa-J0FWT67YuwdiuzNJ0DmS2MHWhrXbGgeUO3G-aptXOGVuA2_EoRI8PQFgFvg1vRnMMMtmZrehMbcHWCDCcT_oNYeBzNpscsNmYTPrZuutXi-kc3JvCinJvNRPd6qfYOWAsGFpVdytdGlGCgS5L9yZ4mYvS6atTvQy-joaLwW14N70ZD7K7UBLIYEiQhAmDmjFFVCxSmYtlIqlKWMRooiEjkZIoUjFVhORM5xAqhZCOE0ygkoRcBh-OvrbN-VoaXgtzqEXN1y3P5osxxziiMYae_Xhkm82y0kpq27Wi5E1rKtHuDsq_X6xZeZ8tj2nMYJp4g-uTQVv_2GjX8co46dsVVtcbx1HK0pj56VKPvvsz6znkaXQeoEdAtrVzrc65NN1hCj7alBxBvt8T7veE7_fEd8EjTg5toH-UT-b_07w_fdPGs1oZ8Sz6Mv00hBSzhCBMfgNScsyM
CitedBy_id crossref_primary_10_1096_fba_2019_00071
crossref_primary_10_1186_s12935_022_02666_z
crossref_primary_10_2147_DDDT_S274980
crossref_primary_10_3390_molecules29071570
crossref_primary_10_3892_mmr_2019_10747
crossref_primary_10_1080_10408398_2022_2121261
crossref_primary_10_1016_j_intimp_2019_02_014
crossref_primary_10_1016_j_intimp_2025_114387
crossref_primary_10_1155_2021_4652492
crossref_primary_10_1097_MS9_0000000000002392
crossref_primary_10_3390_cancers11101618
crossref_primary_10_1111_cas_14168
crossref_primary_10_3390_ijms222212455
crossref_primary_10_2147_DDDT_S284163
crossref_primary_10_3390_pharmaceutics14020256
crossref_primary_10_3390_ijms24108630
crossref_primary_10_1016_j_jnutbio_2021_108634
crossref_primary_10_1038_s41598_020_63232_z
crossref_primary_10_1016_j_phymed_2023_154658
crossref_primary_10_1155_2022_5093486
crossref_primary_10_1016_j_phymed_2022_154413
crossref_primary_10_1002_med_21985
crossref_primary_10_1016_j_biopha_2021_111419
crossref_primary_10_1016_j_jss_2018_08_009
crossref_primary_10_1186_s13020_021_00473_8
crossref_primary_10_1155_2022_5497991
crossref_primary_10_1016_j_ijbiomac_2019_02_003
crossref_primary_10_1016_j_jtcme_2024_04_009
crossref_primary_10_1002_ptr_6577
crossref_primary_10_1016_j_jep_2020_112664
crossref_primary_10_4103_wjtcm_wjtcm_56_24
crossref_primary_10_1016_j_cellsig_2023_110843
crossref_primary_10_1097_MD_0000000000032132
crossref_primary_10_1080_10408398_2022_2155106
crossref_primary_10_1016_j_gene_2019_01_043
ContentType Journal Article
Copyright Copyright © 2017 by The Korean Society of Food Science and Nutrition 2017
Copyright_xml – notice: Copyright © 2017 by The Korean Society of Food Science and Nutrition 2017
DBID DBRKI
TDB
AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.3746/pnf.2017.22.4.320
DatabaseName DBPIA - 디비피아
Nurimedia DBPIA Journals
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2287-8602
EndPage 326
ExternalDocumentID oai_kci_go_kr_ARTI_2247520
PMC5758096
29333385
10_3746_pnf_2017_22_4_320
NODE07286312
Genre Journal Article
GroupedDBID 9ZL
ADBBV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
DBRKI
DIK
GW5
HYE
JDI
KVFHK
OK1
RPM
TDB
AAYXX
CITATION
.UV
NPM
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c3080-31c0680e88d3d5a9cfab6c7d684876e0834dc14d57d33f8ef00dd11e56230dc33
ISSN 2287-1098
IngestDate Wed Jan 22 07:38:00 EST 2025
Thu Aug 21 18:42:00 EDT 2025
Fri Jul 11 14:30:24 EDT 2025
Wed Feb 19 02:44:23 EST 2025
Thu Apr 24 22:59:49 EDT 2025
Tue Jul 01 03:44:00 EDT 2025
Thu Mar 13 19:37:06 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords kaempferol
angiogenesis
HUVECS
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3080-31c0680e88d3d5a9cfab6c7d684876e0834dc14d57d33f8ef00dd11e56230dc33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC5758096
PMID 29333385
PQID 1989587467
PQPubID 23479
PageCount 7
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_2247520
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5758096
proquest_miscellaneous_1989587467
pubmed_primary_29333385
crossref_citationtrail_10_3746_pnf_2017_22_4_320
crossref_primary_10_3746_pnf_2017_22_4_320
nurimedia_primary_NODE07286312
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20171201
PublicationDateYYYYMMDD 2017-12-01
PublicationDate_xml – month: 12
  year: 2017
  text: 20171201
  day: 1
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Preventive nutrition and food science
PublicationTitleAlternate Prev Nutr Food Sci
PublicationYear 2017
Publisher 한국식품영양과학회
The Korean Society of Food Science and Nutrition
Publisher_xml – name: 한국식품영양과학회
– name: The Korean Society of Food Science and Nutrition
References 18463380 - N Engl J Med. 2008 May 8;358(19):2039-49
15602010 - Pharmacol Rev. 2004 Dec;56(4):549-80
10815805 - Oncogene. 2000 Apr 20;19(17 ):2138-46
22260680 - Biochem Soc Trans. 2012 Feb;40(1):139-46
14712224 - Oncogene. 2004 Jan 8;23(1):192-200
9109485 - Nature. 1997 Apr 17;386(6626):671-4
11772931 - FASEB J. 2002 Jan;16(1):2-14
17220336 - Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):98-101
28534212 - Cell Oncol (Dordr). 2017 Jun;40(3):199-208
17471564 - Int J Cancer. 2007 Nov 15;121(10):2225-32
12816951 - J Biol Chem. 2003 Sep 12;278(37):35501-7
18922108 - Expert Opin Investig Drugs. 2008 Nov;17(11):1717-34
12121824 - J Nutr Biochem. 2002 Jul;13(7):380-390
15488631 - Cancer Lett. 2004 Nov 25;215(2):129-40
12039858 - FASEB J. 2002 Jun;16(8):771-80
17583406 - Food Chem Toxicol. 2007 Oct;45(10):2005-13
16254106 - J Clin Pathol. 2005 Nov;58(11):1170-4
16169200 - J Nutr Biochem. 2006 Mar;17(3):165-76
10652234 - Biochem Biophys Res Commun. 2000 Feb 5;268(1):183-91
22144946 - Front Mol Neurosci. 2011 Dec 02;4:51
14603522 - J Cell Physiol. 2004 Feb;198(2):197-208
17344514 - Am J Clin Nutr. 2007 Mar;85(3):895-909
19005980 - Nutr Cancer. 2008;60(6):800-9
21992728 - Future Oncol. 2011 Oct;7(10):1149-67
22193302 - Nat Protoc. 2011 Dec 22;7(1):89-104
16289744 - Toxicol In Vitro. 2006 Mar;20(2):187-210
18590808 - Toxicol Lett. 2008 Aug 28;180(3):166-73
8756616 - Mol Cell Biol. 1996 Sep;16(9):4604-13
15928673 - Nat Rev Cancer. 2005 Jun;5(6):423-35
16336951 - Cardiovasc Res. 2006 Feb 1;69(2):512-9
References_xml – reference: 11772931 - FASEB J. 2002 Jan;16(1):2-14
– reference: 18590808 - Toxicol Lett. 2008 Aug 28;180(3):166-73
– reference: 12816951 - J Biol Chem. 2003 Sep 12;278(37):35501-7
– reference: 15602010 - Pharmacol Rev. 2004 Dec;56(4):549-80
– reference: 16254106 - J Clin Pathol. 2005 Nov;58(11):1170-4
– reference: 12121824 - J Nutr Biochem. 2002 Jul;13(7):380-390
– reference: 22260680 - Biochem Soc Trans. 2012 Feb;40(1):139-46
– reference: 12039858 - FASEB J. 2002 Jun;16(8):771-80
– reference: 16336951 - Cardiovasc Res. 2006 Feb 1;69(2):512-9
– reference: 19005980 - Nutr Cancer. 2008;60(6):800-9
– reference: 17344514 - Am J Clin Nutr. 2007 Mar;85(3):895-909
– reference: 18922108 - Expert Opin Investig Drugs. 2008 Nov;17(11):1717-34
– reference: 16169200 - J Nutr Biochem. 2006 Mar;17(3):165-76
– reference: 15928673 - Nat Rev Cancer. 2005 Jun;5(6):423-35
– reference: 14603522 - J Cell Physiol. 2004 Feb;198(2):197-208
– reference: 17220336 - Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):98-101
– reference: 22144946 - Front Mol Neurosci. 2011 Dec 02;4:51
– reference: 21992728 - Future Oncol. 2011 Oct;7(10):1149-67
– reference: 18463380 - N Engl J Med. 2008 May 8;358(19):2039-49
– reference: 17471564 - Int J Cancer. 2007 Nov 15;121(10):2225-32
– reference: 17583406 - Food Chem Toxicol. 2007 Oct;45(10):2005-13
– reference: 28534212 - Cell Oncol (Dordr). 2017 Jun;40(3):199-208
– reference: 10815805 - Oncogene. 2000 Apr 20;19(17 ):2138-46
– reference: 22193302 - Nat Protoc. 2011 Dec 22;7(1):89-104
– reference: 9109485 - Nature. 1997 Apr 17;386(6626):671-4
– reference: 16289744 - Toxicol In Vitro. 2006 Mar;20(2):187-210
– reference: 8756616 - Mol Cell Biol. 1996 Sep;16(9):4604-13
– reference: 15488631 - Cancer Lett. 2004 Nov 25;215(2):129-40
– reference: 14712224 - Oncogene. 2004 Jan 8;23(1):192-200
– reference: 10652234 - Biochem Biophys Res Commun. 2000 Feb 5;268(1):183-91
SSID ssj0001129527
Score 2.0413055
Snippet Kaempferol has been shown to inhibit vascular formation in endothelial cells. However, the underlying mechanisms are not fully understood. In the present...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
nurimedia
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 320
SubjectTerms 식품과학
Title Kaempferol Inhibits Angiogenesis by Suppressing HIF-1α and VEGFR2 Activation via ERK/p38 MAPK and PI3K/Akt/mTOR Signaling Pathways in Endothelial Cells
URI https://www.dbpia.co.kr/journal/articleDetail?nodeId=NODE07286312
https://www.ncbi.nlm.nih.gov/pubmed/29333385
https://www.proquest.com/docview/1989587467
https://pubmed.ncbi.nlm.nih.gov/PMC5758096
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002303606
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Preventive Nutrition and Food Science, 2017, 22(4), , pp.320-326
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLbYuIAbBOKvAyaD2A1R28RJnPSyjHQr-9Xo0O6sJHa6qJ07devQeBJegxfhmTjHadKUTWjQi7RyHTvS9_nkHPv8EPLe8zthqFLV5BK3bhzZaSaKJU2ecZ4k0Ob7GI28t8-3j73PJ_7JomariS65TFrp91vjSv4HVWgDXDFK9h-QrQaFBvgN-MIVEIbrnTDeidXZeabQ1byvT_MEDwG6ephPhijB8gvULbFsp_F11UNru99rOhub0cZHxxwafI22ekfM6qZljTPrKo-t6GgHS_K6obXXPdwpwgn6LrZ1RyCye2eDgyPrSz5EFR4GPQQd8lt8bfxqIy0xomuM2_Cbajy-qOu-ZbaoK2XpsgaAGT3DzMrzV_HCJ8AQdSsHXqr61gS87hZuHkaCMTDHQM4XZaZLcctYjVZeTXa6Jiruhkx3A5PM-FybhKtBi7GW15r3Xc6fvX8gese7u2IQnQxWyH0WBObgvty_MbtuoN4UdXyrZyuOunGW9o05lpSVFT2F6wM9w7oLsHhvs0n-dK2t6SqDx-TR3Mig3YIxT8g9pZ-SHwu20JIttM4WmlzTGluoYcuvnxQgogVT6IIpFJhCgSlt4AlFnphuyJM2sKSNHKEVR2jJEZprWuMINRx5Ro570WBzuzmvy9FMXTAw4LWdYsUWFYbSlX7cSbM44WkgeQjWL1eg1HsydTzpB9J1s1Blti2l4yhUtW2Zuu5zsqonWr0kFKwTxjPfVjHcFGd-x0sCHksedxjmEEkbxC4BEOk8aT3WThkLMF4RMwGYCcRMMCY8AZg1yIfqlvMiY8vfOr8DVMUozQXmWcfv4USMpgKsyT708gIfO61XoFdD7h98iuyAhdx1WIO8LZkgQDrjkVus1WR2IdAj0Q-xpE-DvCiYUY0AijZ8Qr9BgiXOVB3wiZb_0fmpyQAPNlZod_jaHeZ9RR4uluZrsno5nak3oEdfJutmafwGl1_GNQ
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Kaempferol+Inhibits+Angiogenesis+by+Suppressing+HIF-1%CE%B1+and+VEGFR2+Activation+via+ERK%2Fp38+MAPK+and+PI3K%2FAkt%2FmTOR+Signaling+Pathways+in+Endothelial+Cells&rft.jtitle=Preventive+nutrition+and+food+science&rft.au=Kim%2C+Gi+Dae&rft.date=2017-12-01&rft.issn=2287-1098&rft.volume=22&rft.issue=4&rft.spage=320&rft_id=info:doi/10.3746%2Fpnf.2017.22.4.320&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2287-1098&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2287-1098&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2287-1098&client=summon